Evolving strategies for combined-modality therapy for locally advanced head and neck cancer.
Despite continual advances in the treatment of head and neck cancer, disease-free survival, functional outcome, toxicity of therapy, and overall survival remain less than optimal. While traditional treatment has focused on surgical resection with or without radiation and chemoradiotherapy, newer combined-modality regimens may offer patients a better prognosis, organ preservation, and less morbidity. In this paper, single agents and doublet therapy are reviewed, as are emerging data on the utility of induction therapy, chemoradiotherapy, and surgery as a sequential treatment regimen. Disclosure of potential conflicts of interest is found at the end of this article.
Posner
Marshall
M
Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, SW430, Boston, Massachusetts 02115, USA. marshall_posner@dfci.harvard.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male
D000970:Antineoplastic Agents